Printer Friendly

THE LIPOSOME COMPANY REPRESENTS AT THE HAMBRECHT & QUIST LIFE SCIENCES CONFERENCE

 THE LIPOSOME COMPANY REPRESENTS AT THE
 HAMBRECHT & QUIST LIFE SCIENCES CONFERENCE
 SAN FRANCISCO, Jan. 7 /PRNewswire/ -- Charles A. Baker, chairman and chief executive officer and Dr. Marc J. Ostro, vice chairman and chief science officer of The Liposome Company, Inc. (NASDAQ: LIPO) updated participants at the Hambrecht & Quist Tenth Annual Life Sciences Conference on the company's accomplishments in 1991 and plans for 1992. Ostro introduced TLC C-53, the company's new cell adhesion antagonist being developed for the treatment of a variety of acute inflammatory and vaso-occlusive conditions, while Baker focused primarily on the progress made in Phase II clinical trials of the company's three lead products.
 TLC C-53 is a liposomal prostaglandin E1 (PGE1), which is being developed as a cell adhesion antagonist. Ostro referred to it as a "universal off switch," because TLC C-53 is believed to prevent platelets, neutrophils and endothelial cells from becoming "turned on," and may also deactivate these cells after they have been "turned on," regardless of what stimulatory factors are present. When these cells are "turned off" or deactivated, they will not adhere to the cells to which they otherwise would. By so doing, it appears that TLC C-53 stops the cell adhesion which can lead to a variety of inflammatory and vaso- occlusive conditions including ARDS (Adult Respiratory Distress Syndrome), restenosis following angioplasty, reperfusion injury during Acute Myocardial Infarction (AMI), sepsis/trauma shock syndrome, and others. Ostro presented positive results of animal experiments in models of ARDS and AMI treated with TLC C-53. He said that The Liposome Company plans to start the clinical trials with TLC C-53 in 1992.
 The company's pipeline of research projects also includes a liposomal fibrinolytic agent which it has recently licensed. Dr. Karl E. Arfors has recently joined The Liposome Company as executive director of Biological Sciences. TLC C-53, the liposomal fibrinolytic project, and the addition of Arfors and an expanded Biological Sciences group represent a major expansion of the potential of the company's technology into the inflammation and cardiovascular areas.
 Baker reported Phase II progress for TLC ABLC, TLC G-65, and TLC D- 99. TLC ABLC (Amphotericin B Lipid Complex) has been tested in the treatment of a number of systemic fungal infections which frequently attack AIDS and cancer patients. Indications being studied include systemic candidiasis, cryptococcal meningitis, coccidioidomycosis, aspergillosis, and leishmaniasis. Approximately 200 patients have been treated to date, including some patients in a compassionate use program. Clinical trial sites have included U.S., South America, Europe, and Australia. Positive efficacy and safety results have been seen in these Phase II studies meriting the initiation of Phase III studies. While the drug had been on temporary clinical hold for a short time due to a manufacturing issue, that hold was lifted yesterday by the Food and Drug Administration (FDA). Investigators are being notified that clinical trials are now resuming.
 TLC G-65 is a liposome encapsulated gentamicin in development for the treatment of mycobacterium avium-intracellulare (MAI), a common opportunistic infection which strikes 30-50 percent of persons with AIDS. In Phase II trials to date, the company has seen significant reduction in CFUs (colony forming units) as well as improvements in fevers, nightsweats, and rigors in some patients. The company is now conducting a loading dose study to investigate a more intensive dosing regimen. The company plans to start Phase III trials in Europe early in 1992, looking at TLC G-65 in combination with other drugs. An expanded Phase II efficacy trial is also planned to start in the U.S. early in 1992.
 TLC D-99 is a liposomal doxorubicin, which is in Phase II clinical trials for the treatment of metastatic breast cancer. Studies have demonstrated that in an animal model of breast cancer, TLC D-99 delivers levels of doxorubicin to the tumor which are much higher than those achieved with conventional doxorubicin. It has also been demonstrated in animal studies that TLC D-99 did not cause the severe cardiotoxicity seen with free doxorubicin. In the Phase II metastatic breast cancer study to date, the company is very pleased with the response rates as well as with the continuing verification of the low toxicity profile shown in Phase I studies, and it was reported that a clinical abstract had been submitted to the American Society of Clinical Oncology meeting to held in May. Myelosuppression has continued to be the dose limiting toxicity. Plans for 1992 for TLC D-99 include an expanded metastatic breast cancer trial involving approximately 10 centers.
 The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment and diagnosis of life-threatening illnesses.
 -0- 1/7/92
 /CONTACT: Anne Van Lent senior vice president and CFO of The Liposome Company, Inc., 609-452-7060/
 (LIPO) CO: Liposome Company Inc. ST: New Jersey, California IN: MTC SU:


SM-KW -- NY020 -- 7301 01/07/92 12:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1992
Words:812
Previous Article:CAMRY SE, AXV-IV CONCEPT CAR STAR ATTRACTIONS OF 50-CAR TOYOTA DISPLAY AT NORTH AMERICAN INTERNATIONAL AUTO SHOW
Next Article:DIGICON ANNOUNCES SALE OF COMMON STOCK
Topics:


Related Articles
HEALTHCARE INDUSTRY TO UNDERGO SIGNIFICANT CHANGES OVER NEXT 10 YEARS, HAMBRECHT & QUIST FORECASTS
DIANON SYSTEMS SELECTED AS ANALYST'S NO. 1 HEALTH CARE COMPANY AT THE HAMBRECHT & QUIST HEALTH CARE CONFERENCE
HAMBRECHT and QUIST OPENS 20TH ANNUAL TECHNOLOGY CONFERENCE TODAY
LIPOSOME COMPANY, INC. COMPLETES $57 MILLION PREFERRED STOCK OFFERING
THE LIPOSOME COMPANY FILES FOR APPROVAL OF ABLC IN EUROPE
THE LIPOSOME COMPANY, INC. FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING OF 3,000,000 SHARES OF COMMON STOCK
RECORD 180 COMPANIES TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE
U.S. BIOSCIENCE TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE
HAMBRECHT & QUIST, FINANCIERE SAINT DOMINIQUE AND BEESON GREGORY SPONSOR FIRST EUROPEAN GROWTH COMPANY CONFERENCE IN PARIS
TARGETED GENETICS COMPLETES FOUR NEW GENE THERAPY CLINICAL TRIALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters